{
  "meta": {
    "title": "Radiotherapy",
    "url": "https://brainandscalpel.vercel.app/radiotherapy-c312e91d.html",
    "scrapedAt": "2025-11-30T11:20:40.173Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Alpha rays</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Beta rays</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Gamma rays</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">X-rays</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old man with squamous cell carcinoma of the oropharynx is scheduled to undergo external beam radiotherapy. As part of pre-treatment counselling, he asks about the type of radiation that will be used to target the tumour. Which of the following types of radiation is most commonly used in external beam radiotherapy?</span></p>",
      "unique_key": "DT1282645",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282645,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>X-rays</strong> are the most commonly used type of radiation in <strong>radiotherapy</strong>. High-energy (megavoltage, MV) systems are used for cancer therapy because their beams spare the skin and readily penetrate tissue.</p>\n<ul>\n<li>X-rays in EBRT are generated by a <strong>linear accelerator (LINAC).</strong><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025072444f7cfed-4460-4e8c-b7f3-db6383626757.png\"></li>\n<li>They are a type of electromagnetic radiation with <strong>high energy </strong>that can penetrate tissues and deliver<strong> therapeutic doses of radiation </strong>to target tumours while minimizing damage to surrounding healthy tissues.</li>\n<li>Three main types of radiation are used for Radiotherapy/Teletherapy: <strong>X-rays &gt; &gamma;- &gamma;-rays</strong>, and <strong>electrons</strong>.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Alpha rays (Option A)</strong>: Heavy particles with low penetration, unsuitable for deep tissue treatment.</p>\n<p><strong>Beta rays (Option B)</strong>: Used in specific therapies (e.g., surface treatments), but less common than X-rays in EBRT.</p>\n<p><strong>Gamma rays (Option C)</strong>: Used in brachytherapy or stereotactic radiosurgery, but X-rays dominate in EBRT.</p>\n<p><strong>Reference:</strong></p>\n<p><a href=\"https://www.physicamedica.com/article/S1120-1797(20)30275-1/fulltext#:~:text=x%2Drays%20are%20preferred%20over%20higher%20energy%20photons%20due%20to%20their%20reduced%20penetration%2C%20which%20reduces%20dose%20to%20normal%20tissues%20beyond%20the%20tumor%20site\">https://www.physicamedica.com/article/S1120-1797(20)30275-1/fulltext#:~:text=x%2Drays%20are%20preferred%20over%20higher%20energy%20photons%20due%20to%20their%20reduced%20penetration%2C%20which%20reduces%20dose%20to%20normal%20tissues%20beyond%20the%20tumor%20site</a></p>",
      "correct_choice_id": 4,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Electrons</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Protons</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Neutrons</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">X-ray</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 7-year-old child with medulloblastoma is being considered for a specialised form of radiotherapy that minimises radiation to surrounding healthy brain tissue. The oncologist explains that this technique relies on the Bragg peak phenomenon. Which type of radiation exhibits the Bragg peak, delivering maximal energy deposition at a specific depth within tissues?</span></p>",
      "unique_key": "DT1282648",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282648,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation of answer:</strong></p>\n<p><strong>Protons </strong>exhibit a<strong> Bragg peak.</strong></p>\n<ul>\n<li>The proton is a heavy and charged particle that gradually loses its speed as it interacts with human tissue. It is easily&nbsp;controlled and delivers its<strong> maximum dose at a precise depth </strong>and can go as far as 32 cm.</li>\n<li>The absorbed dose increases very gradually with greater depth and lower speed, suddenly rising to a peak when the proton is ultimately stopped. This is known as the&nbsp;<strong>Bragg Peak.</strong></li>\n<li>The behaviour of the proton can be precisely determined, and the beam directed to the<strong> Bragg peak </strong>occurs exactly within the tumour site. Immediately after this burst of energy, the proton completely stops to&nbsp;<strong>irradiate and the particles come to rest</strong>.</li>\n<li><strong>Proton therapy</strong>, therefore, allows for targeting tumours inside the body, precisely <strong>localising the radiation dosage</strong> and sparing the patient's healthy cells, offering a much less invasive alternative to treat cancer.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025072215d1730c-a35b-47c5-a002-292aa1331c72.png\">",
      "correct_choice_id": 12,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Brachytherapy</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Teletherapy</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Radioactive iodine therapy </span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Stereotactic radiotherapy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old woman with carcinoma of the cervix is planned for internal radiotherapy using a technique that ensures minimal radiation exposure to healthcare workers. The radiation oncologist mentions that the source will be inserted remotely after the applicators are placed. Which of the following techniques uses a remote after-loading system for radiation delivery?</span></p>",
      "unique_key": "DT1282651",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282651,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation of answer:</strong></p>\n<ul>\n<li><strong>Brachytherapy </strong>uses a remote after-loading system for radiation delivery.</li>\n<li>Remote after-loading in <strong>high-dose-rate (HDR) brachytherapy</strong> involves placing applicators in the body, followed by remote insertion of radioactive sources (e.g., Iridium-192) to minimise staff exposure.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025072202842459-b340-49ba-9859-a9b2d9142096.png\">\n<ul>\n<li>Used in cancers like cervical, prostate, breast, and head &amp; neck.</li>\n<li>Can be delivered via low-dose rate (LDR) or high-dose rate (HDR) systems.</li>\n<li>In remote after-loading, applicators are first positioned in the body, and the radioactive source is loaded remotely to protect healthcare workers.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Teletherapy (Option B)</strong>: Uses external beam radiation (e.g., LINACs), not remote after-loading.</p>\n<p><strong>Radioactive iodine therapy (Option C):</strong>&nbsp;Systemic treatment for thyroid conditions, not involving applicators.</p>\n<p><strong>Stereotactic radiotherapy (Option D)</strong>: Precise external beam therapy, not using after-loading.</p>",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">G2M</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">S</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">G1</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">M</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is the most radioresistant phase of the cell cycle?<br> <img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202507224f8ab047-b19b-4dbf-a394-4f8393568990.png\"></span></p>",
      "unique_key": "DT1282653",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282653,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation of answer:</strong></p>\n<p><strong>Radioresistant Phase:</strong></p>\n<ul>\n<li>The<strong> S (synthesis) phase</strong> is the <strong>most radioresistant</strong> due to active DNA repair mechanisms, allowing cells to repair radiation-induced damage before division.</li>\n</ul>\n<p><strong>Radiosensitive Phase:</strong></p>\n<ul>\n<li>Radiosensitivity peaks in <strong>G2M</strong> and <strong>M phases</strong> due to DNA condensation and mitotic vulnerability.<strong> (Options A &amp; D ruled out)<br /> <img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202507222a9677c7-34cc-4cf6-a46b-86695719e0c0.png\">\n</strong></li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>G1 (Options C):</strong> Moderately radiosensitive; cells are preparing for DNA replication.</p>\n<p><strong>Reference:</strong></p>\n<p><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8579106/\">https://pmc.ncbi.nlm.nih.gov/articles/PMC8579106/</a></p>",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Oxygen</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Metronidazole</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Misonidazole</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 58-year-old man with squamous cell carcinoma of the hypopharynx is planned for radiotherapy. To improve the effectiveness of the treatment in hypoxic tumour areas, a radiosensitizing agent is considered. Which of the following agents is known to enhance the effect of radiation therapy by acting as a radiosensitizer?</span></p>",
      "unique_key": "DT1282655",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282655,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation of answer:</strong></p>\n<ul>\n<li><strong>Radiosensitizers</strong> are substances that enhance the effects of radiation on tumour cells, especially in hypoxic environments where radiotherapy is less effective.</li>\n<li><strong>Oxygen</strong> is the most effective <strong>natural radiosensitizer</strong>, improving DNA damage via free radical formation. <strong>(Option A)</strong></li>\n<li><strong>Metronidazole and Misonidazole</strong> are nitroimidazole derivatives that mimic oxygen's effect and sensitize hypoxic tumour cells by enhancing radiation-induced DNA damage. <strong>(Option B &amp; C)</strong></li>\n<li><strong>Radiosensitizers include: (Mnemonic: </strong><strong>'5-COG</strong>Ni')\n<ul>\n<li><strong>5</strong>- Fluorouracil;</li>\n<li><strong>C</strong>isplatin, <strong>C</strong>ytochlor;</li>\n<li>Hyperbaric <strong>O</strong><sub>2</sub>;</li>\n<li><strong>G</strong>emcitabine;</li>\n<li><strong>Ni</strong>troimidazoles- Metronidazole, Misonidazole, Pimonidazole,</li>\n</ul>\n</li>\n<li><strong>Radioprotectants:</strong>\n<ul>\n<li><strong>Radioprotectors </strong>are substances that protect normal tissues from the effects of radiation.</li>\n<li>These include: <strong>(Mnemonic: PEZA (pizza) CAMP)</strong>\n<ul>\n<li><strong>P</strong>entoxifylline</li>\n<li><strong>E</strong>stramustine</li>\n<li><strong>Z</strong>inc oxide</li>\n<li><strong>A</strong>mifostine</li>\n<li><strong>C</strong>hlorhexidine</li>\n<li><strong>A</strong>ntioxidants</li>\n<li><strong>M</strong>elatonin</li>\n<li><strong>P</strong>otassium</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><strong>Radiation Potentiators:</strong>\n<ul>\n<li>The following drugs potentiate the action of radiation when used in conjunction:\n<ul>\n<li>Doxorubicin</li>\n<li>Dactinomycin</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>",
      "correct_choice_id": 44,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Haematological symptoms</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">CNS symptoms</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Gastrointestinal symptoms</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following symptom complexes may be seen in acute radiation sickness, depending on the dose of exposure?</span></p>",
      "unique_key": "DT1282656",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282656,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>All of them are characteristics of<strong> Acute radiation sickness.</strong></p>\n<p><strong>Acute radiation sickness (ARS) </strong>occurs after high-dose whole-body radiation exposure and presents in phases depending on dose:</p>\n<ul>\n<li><strong>1-2 Gy: Hematopoietic syndrome: </strong>Bone marrow suppression, pancytopenia.</li>\n<li><strong>5-10 Gy: Gastrointestinal syndrome: </strong>Nausea, vomiting, diarrhoea, mucosal sloughing.</li>\n<li><strong>&gt;20-30 Gy: CNS Syndrome: </strong>Confusion, seizures, coma, death within hours to days.</li>\n<li><strong>Hematopoietic Syndrome (1-2.5 Gy): (Option A)</strong>\n<ul>\n<li>Most sensitive to radiation.</li>\n<li>Occurs due to the destruction of bone marrow stem cells.</li>\n<li>This leads to<strong> pancytopenia</strong>, increasing the risk of infections, bleeding, and anemia.</li>\n<li><strong>Onset: </strong>within<strong> 1-2 weeks </strong>after exposure.</li>\n<li>Survivable with supportive care and possibly a<strong> bone marrow transplant.</strong></li>\n</ul>\n</li>\n<li><strong>Gastrointestinal (GI) Syndrome (5-10 Gy): (Option B)</strong>\n<ul>\n<li>Damage to rapidly dividing intestinal crypt cells.</li>\n<li><strong>Symptoms: </strong>Nausea, vomiting, diarrhoea, dehydration, electrolyte imbalance, and sepsis due to loss of the mucosal barrier.</li>\n<li>Appear<strong>s within hours to a day.</strong></li>\n<li>Usually fatal within 1-2 weeks without aggressive support.</li>\n</ul>\n</li>\n<li><strong>Cerebrovascular / CNS Syndrome (&gt;20-30 Gy): (Option C)</strong>\n<ul>\n<li>Seen with very high doses, often lethal<strong> within hours to 1-2 days.</strong></li>\n<li><strong>Symptoms: </strong>Confusion, ataxia, seizures, coma, and cardiovascular collapse.</li>\n<li>Caused by damage to neurons, vasculature, and oedema.</li>\n<li>No effective treatment.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Reference:</strong></p>\n<p><a href=\"https://my.clevelandclinic.org/health/diseases/24328-radiation-sickness\">https://my.clevelandclinic.org/health/diseases/24328-radiation-sickness</a></p>",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Sebaceous cyst</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Arterio-venous malformation</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Meningioma</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Acoustic schwannoma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old woman presents with progressive unilateral hearing loss. MRI reveals a small vestibular schwannoma confined to the internal auditory canal. The neurosurgeon recommends a non-invasive treatment using focused radiation. Which of the following conditions is NOT treated using Gamma Knife radiosurgery?</span></p>",
      "unique_key": "DT1282659",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282659,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation of the answer:</strong></p>\n<p><strong>Sebaceous cysts </strong>are treated by simple surgical excision.</p>\n<ul>\n<li><strong>Gamma Knife radiosurgery </strong>is a non-invasive, high-precision form of stereotactic radiosurgery (SRS).</li>\n<li>It uses focused beams of<strong> gamma radiation</strong>, often from Cobalt-60 sources, to treat intracranial lesions.</li>\n<li><strong>Conditions commonly treated with Gamma Knife:</strong>\n<ul>\n<li><strong>Arteriovenous Malformation (AVM): (Option B)</strong>\n<ul>\n<li>Gamma Knife is effective in obliterating small AVMs by causing endothelial damage and vessel sclerosis.</li>\n<li>Especially used when surgery is high-risk due to location.</li>\n</ul>\n</li>\n<li><strong>Meningioma: (Option C)</strong>\n<ul>\n<li>Often used in skull base meningiomas, especially when surgery is difficult or as adjuvant therapy.</li>\n<li>Helps prevent regrowth with minimal damage to the adjacent brain.</li>\n</ul>\n</li>\n<li><strong>Acoustic Schwannoma (Vestibular Schwannoma): (Option D)</strong>\n<ul>\n<li>The Gamma Knife is a standard treatment for small to medium-sized tumours, especially in patients not fit for surgery.</li>\n<li>Preserves hearing and facial nerve function in many cases.</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>",
      "correct_choice_id": 61,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Arc technique</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Modulation</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Gating</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Shunting</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following radiotherapy techniques is specifically used to minimise radiation exposure to normal tissues by accounting for tumour motion due to respiration?</span></p>",
      "unique_key": "DT1282662",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282662,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation of answer:</strong></p>\n<ul>\n<li><strong>Gating&nbsp;</strong>is a technique used in radiotherapy&nbsp;to synchronise the delivery of radiation with the respiratory cycle, particularly to <strong>counteract the motion of tumours caused by breathing.</strong></li>\n<li><strong>Technique:</strong>\n<ul>\n<li>The patient's breathing is monitored using sensors or imaging.</li>\n<li>Tumor position is tracked in real-time.</li>\n<li>The radiation beam is turned on only when the tumour is within the target zone.</li>\n<li>This improves accuracy and spares normal tissue.</li>\n</ul>\n</li>\n<li><strong>Benefits:</strong>\n<ul>\n<li>Increases precision of dose delivery.</li>\n<li>Reduces radiation-induced toxicity to surrounding organs like lungs, heart, or liver.</li>\n<li>Especially useful in lung and upper abdominal cancers.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options: </strong></p>\n<p><strong>Arc technique (Option A)</strong>: It involves&nbsp;delivering radiation to the tumour from multiple angles while the treatment machine rotates around the patient. While this technique can help deliver radiation to moving targets, it does not specifically address tumour motion due to breathing.</p>\n<p><strong>Modulation (Option B)</strong> refers to techniques such as intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT), which optimise the intensity or shape of the radiation beam to conform to the shape of the tumour while sparing surrounding healthy tissues. While these techniques can improve treatment precision, they do not specifically address tumour motion due to breathing.</p>\n<p><strong>Shunting (Option D)</strong> refers to the&nbsp;surgical placement of a device to redirect the flow of bodily fluids, such as cerebrospinal fluid, in the case of hydrocephalus. It is not a technique used in radiotherapy to account for tumour motion due to breathing.</p>",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Obturator nodes</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Mackenrodt's ligament</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Ischial tuberosity</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Round ligament</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old woman is diagnosed with stage IIB carcinoma of the cervix. She is planned for external beam radiotherapy followed by intracavitary brachytherapy. During treatment planning, the radiation oncologist mentions the importance of targeting \"Point B\" to ensure adequate nodal coverage. Point B in the radiotherapy of carcinoma cervix in the given image corresponds to which of the following anatomical structures?<br> <img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202507222a33fae7-69af-44c1-a1c3-c3e5c7ebbcb4.png\"></span></p>",
      "unique_key": "DT1282665",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282665,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation of answer:</strong></p>\n<p>The given image is the brachytherapy of Ca cervix, the<strong> point B</strong> corresponds to the&nbsp;<strong>Obturator nodes.</strong></p>\n <img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202507222a33fae7-69af-44c1-a1c3-c3e5c7ebbcb4.png\">\n<ul>\n<li><strong>Point A</strong>: 2 cm above and 2 cm lateral (from midline) to the external cervical os, denotes crossing of uterine artery and ureter. Early stage (80-85 Gy); advanced stage (85-90 Gy)</li>\n<li><strong>Point B:</strong>5 cm (from midline) in the same plane as Point A, denotes the obturator node. Early stage (50-55 Gy); advanced stage (55-60 Gy).\n<ul>\n<li><strong>Clinical Importance:</strong>\n<ul>\n<li>Ensures that pelvic lymph node basins, especially the obturator group, receive adequate radiation.</li>\n<li>Important for locoregional control in advanced-stage cervical cancers.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><strong>Points A and B </strong>are dosimetric reference points in cervical cancer brachytherapy.<br /> </li>\n</ul>",
      "correct_choice_id": 81,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Both A and R are true, and R is the correct explanation of A</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Both A and R are true, but R is not the correct explanation of A</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">A is true, but R is false</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">A is false, but R is true</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\"><strong>Assertion (A):</strong> Prophylactic cranial irradiation (PCI) is administered in patients with small cell lung carcinoma (SCLC) who have responded to initial therapy.<br /><strong>Reason (R):</strong> Small cell lung carcinoma has a high propensity for early brain metastasis, even when the primary tumour is controlled.<br />Choose the correct answer:</span></p>",
      "unique_key": "DT1282669",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282669,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Prophylactic cranial irradiation (PCI)</strong> is given in <strong>small cell lung carcinoma (SCLC) </strong>to reduce the risk of brain metastases in patients who have shown a good response to chemotherapy and/or radiotherapy. Hence the assertion is true.</li>\n<li><strong>SCLC</strong> is a highly aggressive tumour with a very early tendency to <strong>metastasise to the brain</strong>, due to its neuroendocrine nature. Hence the reason is true.</li>\n<li>The blood-brain barrier limits the penetration of chemotherapy, making prophylactic irradiation crucial for prevention.</li>\n<li>The reason directly explains why PCI is given in SCLC,&nbsp; to preemptively treat potential micrometastases in the CNS due to the high risk of spread.<br /> </li>\n</ul>",
      "correct_choice_id": 91,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Nephroblastoma</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Multiple Myeloma</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Malignant melanoma</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Ewing's sarcoma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following tumours is known to be least sensitive to ionising radiation?</span></p>",
      "unique_key": "DT1282670",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282670,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Malignant melanoma</strong> is <strong>highly radioresistant </strong>due to efficient DNA repair mechanisms.</li>\n<li>Malignant melanoma is a type of skin cancer that arises from<strong> melanocytes, </strong>the pigment-producing cells of the skin.</li>\n<li>While radiation therapy can be used as a treatment modality for melanoma in certain situations, it is generally less effective compared to other treatment options such as <strong>surgery or immunotherapy.</strong></li>\n</ul>\n<p><strong>Radiosensitive Tumours:</strong></p>\n<ul>\n<li>Wilms (Nephroblastoma) <strong>(Option A)</strong></li>\n<li>Ewing's sarcoma <strong>(Option D)</strong></li>\n<li>Lymphoma</li>\n<li>Multiple Myeloma <strong>(Option B)</strong></li>\n<li>Seminoma</li>\n</ul>\n<p><strong>Radioresistant Tumours:</strong></p>\n<ul>\n<li>HCC</li>\n<li>Osteosarcoma</li>\n<li>Melanoma <strong>(Option C)</strong></li>\n<li>Pancreatic carcinoma</li>\n</ul>",
      "correct_choice_id": 103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperfractionated Radiotherapy</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypofractionated Radiotherapy</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Accelerated Radiotherapy</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Regular Fractionated Radiotherapy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A cancer patient undergoing Radiotherapy is given a dose of 1.8-2 Gy once daily for 5 days per week for 6-8 weeks. What is this type of radiotherapy called?</span></p>",
      "unique_key": "DT1282672",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282672,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>In<strong> Regular Fractionated Radiotherapy/Conventional Radiotherapy</strong>, the patient is given a radiation dose of<strong>&nbsp;1.8-2 Gy </strong>once daily for 5 days per week for 6-8 weeks.</p>\n<ul>\n<li>This is the standard radiotherapy schedule used in many solid tumours like breast, lung, head &amp; neck cancers.</li>\n<li><strong>Conventional fractionation </strong>optimises tumour control while allowing normal tissue repair.</li>\n<li>Allows repair of sublethal damage in normal tissues and reoxygenation of tumour cells between fractions.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Hypofractionated radiotherapy (Option A):</strong> Uses larger doses (&gt;2 Gy) per fraction over fewer sessions.</p>\n<p><strong>Hyperfractionated radiotherapy (Option B): </strong>Uses smaller doses (&lt;2 Gy) per fraction given more than once daily.</p>\n<p><strong>Accelerated radiotherapy (Option C):</strong> Same total dose given over a shorter duration to reduce tumour repopulation.</p>",
      "correct_choice_id": 114,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Hair loss</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Skin erythema</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Nausea and vomiting</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Amnesia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old man with squamous cell carcinoma of the larynx is undergoing external beam radiotherapy to the neck. After 2 weeks of treatment, he reports redness and mild discomfort over the irradiated skin area. Which of the following is the most likely and most common side effect of radiotherapy in this patient?</span></p>",
      "unique_key": "DT1282674",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282674,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The most common side effect of radiotherapy is skin erythema. The following table enlists organ wise side effects of radiotherapy.</p>\n<ul>\n<li>Most common side effect of radiotherapy -<strong>skin erythema</strong></li>\n<li>Most common cancer after radiotherapy -<strong>leukemia</strong></li>\n<li>most common thyroid cancer after radiotherapy - <strong>Papillary thyroid cancer</strong></li>\n<li>most common bone tumor after radiotherapy- <strong>Osteosarcoma</strong><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025072231e1cba9-2c3b-466a-ae6d-2a3c2686d846.png\"></li>\n</ul>\n<p><strong>(Options A, B, C and D) </strong>All of the following are the side effects, where as the most</p>\n<p>Common is skin erythema.</p>",
      "correct_choice_id": 122,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Meningioma</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteosarcoma</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Leukemia</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Papillary carcinoma thyroid</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 12-year-old child was treated for medulloblastoma with craniospinal irradiation and chemotherapy. Five years later, he presents with fatigue and unexplained bruising. Investigations reveal pancytopenia and blast cells in the peripheral smear. Which of the following is the most likely radiation-induced secondary malignancy in this patient?</span></p>",
      "unique_key": "DT1282676",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282676,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Leukaemia</strong>, particularly <strong>acute myeloid leukaemia (AML)</strong>, is the most common secondary malignancy after radiotherapy.</p>\n<ul>\n<li>Arises due to radiation damage to hematopoietic stem cells in bone marrow.</li>\n<li>Typically appears 3-7 years after exposure to high-dose radiation.</li>\n<li><strong>High-risk settings:</strong>\n<ul>\n<li>Pediatric cancers are treated with craniospinal irradiation, total body irradiation, or radiation to long bones and pelvis.</li>\n<li>Chemotherapy + Radiotherapy increases risk (especially alkylating agents).</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Meningioma (Option A): </strong>Can occur after CNS radiation, but is less common than leukaemia; occurs much later (10-15 years).</p>\n<p><strong>Osteosarcoma (Option B):</strong> Known radiation-induced solid tumour, but less frequent than hematologic malignancies.</p>\n<p><strong><strong>Papillary carcinoma thyroid (Option D):</strong> Seen after neck radiation (especially in children), but leukaemia is more common overall.<br /> </strong></p>",
      "correct_choice_id": 133,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">110 min</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">8 days</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">13 hours</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">5.2 years</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the half-life of cobalt-60?</span></p>",
      "unique_key": "DT1282677",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282677,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The half-life of cobalt-60<strong>&nbsp;</strong>(Co-60) is approximately<strong>&nbsp;5.2 years.</strong>&nbsp;</p>\n<ul>\n<li>This means that it takes <strong>2 years</strong> for half of the radioactive atoms in a sample of cobalt-60 to undergo radioactive decay and transform into another element or isotope.</li>\n<li>Cobalt-60 is commonly used in various applications:\n<ul>\n<li>Cancer treatment (radiotherapy), industrial radiography, and sterilisation, due to its&nbsp;<strong>gamma radiation properties </strong>and relatively short half-life.</li>\n</ul>\n</li>\n<li>T&frac12; of a few important substances:\n<ul>\n<li>18F-FDG:110 min <strong>(Option A)</strong></li>\n<li>Tc99m: 6 hours</li>\n<li>I<sup>131</sup>: 8days <strong>(Option B)</strong></li>\n<li>I<sup>125</sup>: 60 days</li>\n<li>I<sup>124</sup>: 4 days</li>\n<li>I<sup>123</sup>: 13 hours <strong>(Option C)</strong></li>\n<li>Cobalt 60: 5.2years</li>\n</ul>\n</li>\n</ul>\n<p><strong>Reference:</strong><br /> <a href=\"https://pubmed.ncbi.nlm.nih.gov/30900636/\">https://pubmed.ncbi.nlm.nih.gov/30900636/</a></p>",
      "correct_choice_id": 144,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Echocardiogram</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Radionuclide scan</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">ECG</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Endomyocardial biopsy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 50-year-old woman with breast cancer is undergoing chemotherapy with doxorubicin and chest wall radiotherapy. She is monitored for signs of cardiotoxicity during follow-up. Which of the following is the best method to assess the extent of cardiac dysfunction in this setting?</span></p>",
      "unique_key": "DT1282679",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282679,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Radionuclide ventriculography (MUGA scan)</strong> is considered the <strong>gold standard</strong> for assessing left ventricular ejection fraction (LVEF) with high reproducibility, especially when monitoring cardiotoxicity due to chemotherapy and radiotherapy.</li>\n<li><strong>MUGA</strong> is preferred because:\n<ul>\n<li>Quantitative and highly reproducible measurement of LVEF, unlike echocardiogram which can have inter-observer variability.</li>\n<li>Ideal for serial monitoring in patients on<strong> cardiotoxic agents </strong>like anthracyclines (e.g., doxorubicin), trastuzumab, and those receiving mediastinal radiotherapy.</li>\n<li>Detects subclinical decline in LVEF before symptoms of heart failure arise.</li>\n</ul>\n</li>\n<li><strong>Clinical significance of MUGA:</strong>\n<ul>\n<li>Baseline LVEF is assessed before starting therapy.</li>\n<li>Follow-up scans are done at regular intervals (e.g., every 3 months) or if symptoms suggest cardiac dysfunction.</li>\n<li>A significant drop in LVEF (&ge;10% to below normal) may lead to modification or discontinuation of therapy.</li>\n</ul>\n</li>\n<li><strong>Advantages over other methods are:</strong>\n<ul>\n<li>More precise than echocardiography, especially in borderline or subtle changes.</li>\n<li>Non-invasive, with minimal discomfort.</li>\n<li>Can detect early, asymptomatic dysfunction.</li>\n</ul>\n</li>\n<li><strong>Limitations are:</strong>\n<ul>\n<li>Involves ionizing radiation, though the dose is low.</li>\n<li>Not useful for assessing diastolic function, valvular disease, or myocardial tissue characteristics.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Echocardiogram (Option A): </strong>Commonly used and non-invasive, but has operator-dependent variability. Though good for general cardiac function assessment, it's less precise than the UGA scan for serial monitoring of LVEF.</p>\n<p><strong>ECG (Option C): </strong>Detects electrical abnormalities such as arrhythmias, ischemia, or conduction delays. It does not measure LVEF or give structural information. Often remains normal even in significant cardiac dysfunction, so not reliable for detecting chemotherapy-induced cardiomyopathy.</p>\n<p><strong>Endomyocardial biopsy (Option D): </strong>Highly invasive and used only in select cases, like suspected myocarditis or transplant rejection. But not suitable for routine monitoring of cardiotoxicity. It is rarely performed in oncology settings due to risk and limited diagnostic yield.</p>",
      "correct_choice_id": 152,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Phosphorus-32</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Iodine-131</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Strontium-89</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Samarium-153</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An elderly patient diagnosed with Polycythemia Vera is not a suitable candidate for repeated phlebotomy or cytotoxic chemotherapy. Which of the following radiopharmaceuticals is most appropriately used for myelosuppression in this setting?</span></p>",
      "unique_key": "DT1282683",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282683,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Radioactive phosphorus (P-32)</strong> is a beta-emitting radiopharmaceutical that was historically used and still occasionally is, in the treatment of <strong>Polycythemia Vera (PV),</strong> especially in:</p>\n<ul>\n<li>Elderly patients, those who are not candidates for repeated phlebotomy or cytotoxic agents like hydroxyurea.</li>\n<li><strong>Mechanism:</strong>\n<ul>\n<li>P-32 localises to bone marrow, where it emits beta radiation, selectively suppressing myeloproliferative.</li>\n<li>It reduces erythrocytosis, leukocytosis, and thrombocytosis, controlling hematocrit levels.</li>\n</ul>\n</li>\n<li><strong>Clinical Use:</strong>\n<ul>\n<li>Given as an oral or IV dose, often repeated after 3-6 months.</li>\n<li>The effect lasts months to years, making it suitable for patients needing long-term hematocrit control.</li>\n<li>Used when low-to-moderate intensity therapy is appropriate.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Iodine-131 (Option B)</strong>: Used for thyroid disorders, particularly thyroid cancer and hyperthyroidism&mdash;not for hematologic conditions.</p>\n<p><strong>Strontium-89 (Option C)</strong>: Beta emitter used for pain palliation in bone metastases, not for marrow suppression.</p>\n<p><strong>Samarium-153 (Option D)</strong>: Also used for skeletal metastases in cancers like prostate or breast cancer; not indicated in PV.</p>",
      "correct_choice_id": 161,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">8 Gy in one fraction</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">20 Gy in 5 fractions</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">30 Gy in 10 fractions</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Above 70 Gy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What dose of radiation therapy is recommended for pain relief in bone metastases?</span></p>",
      "unique_key": "DT1282684",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282684,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>8 Gy </strong>in<strong> one fraction </strong>is the dose of radiation therapy used for pain relief in bone metastasis.</p>\n<ul>\n<li>For <strong>palliative treatment of bone metastases</strong>, the goal is to relieve pain and improve quality of life while minimizing treatment burden.</li>\n<li>Clinical trials demonstrate that a <strong>single fraction of 8 Gy </strong>can provide<strong> effective pain relief </strong>for most patients with <strong>bone metastases. </strong></li>\n<li>This approach is convenient and reduces the need for multiple hospital visits, which is particularly beneficial for patients with advanced cancer.</li>\n</ul>",
      "correct_choice_id": 171,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Phosphorus-32</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Strontium-89</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Iridium-192</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Samarium-153</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old male with widespread bone metastases is experiencing severe pain. He is referred to nuclear medicine for palliative systemic radionuclide therapy. Which of the following radioisotopes is not used as a systemic radionuclide for such therapeutic purposes?</span></p>",
      "unique_key": "DT1282687",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282687,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Iridium-192 </strong>is used in <strong>brachytherapy</strong> and not in systemic radionuclide therapy.</p>\n<ul>\n<li><strong>Iridium-192</strong> is a gamma and beta emitter and is most commonly used in high-dose-rate (HDR) or low-dose-rate (LDR) interstitial implants for localised tumours such as cervical, breast, and prostate cancers.</li>\n<li>It is not administered systemically.</li>\n<li>It is placed close to or within the tumour with catheters or applicators and delivers focused radiation to the tumour while sparing surrounding normal tissue.</li>\n<li><strong>Systemic radionuclides</strong> are administered intravenously and are distributed through the bloodstream to target specific tissues (e.g., bone or bone metastases).</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Phosphorus-32 (Option A) </strong>is a&nbsp;beta emitter&nbsp;and is&nbsp;used in systemic radionuclide therapy, particularly for the treatment of certain blood disorders like&nbsp;polycythemia vera and thrombocythemia.</p>\n<p><strong>Strontium-89 (Option B) </strong>is a&nbsp;beta emitter&nbsp;and is&nbsp;used in systemic radionuclide therapy for the&nbsp;palliative treatment of painful bone metastases, particularly from prostate cancer and breast cancer.</p>\n<p><strong>Samarium-153 (Option D)</strong>&nbsp;is a<strong>&nbsp;</strong>beta emitter&nbsp;and is&nbsp;used in systemic radionuclide&nbsp;therapy for the&nbsp;palliative treatment of painful bone metastases.</p>",
      "correct_choice_id": 183,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">131 I</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">99mTc</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">32 P</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">131 I-MIBG</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 40-year-old woman undergoes total thyroidectomy for papillary carcinoma of the thyroid. Postoperative imaging shows residual thyroid tissue. Which of the following radioisotopes is most commonly used for treatment in this condition?</span></p>",
      "unique_key": "DT1282690",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282690,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Iodine-131 (&sup1;&sup3;&sup1; I)</strong> is the standard radioisotope used therapeutically in differentiated thyroid cancers such as<strong> papillary and follicular carcinoma.</strong></li>\n<li>It retains the ability to uptake iodine.</li>\n<li><strong>After thyroidectomy, &sup1;&sup3;&sup1; I is given to:</strong>\n<ul>\n<li>Ablate residual thyroid tissue</li>\n<li>Treat micrometastases</li>\n<li>Improve long-term outcomes and surveillance (thyroglobulin monitoring)</li>\n</ul>\n</li>\n<li>&sup1;&sup3;&sup1; I emit both <strong>beta particles</strong> (therapeutic) and <strong>gamma rays</strong> (imaging), making it useful for therapeutic and diagnostic purposes: for both treatment and post-therapy scanning.</li>\n<li>Patients are often pre-treated with <strong>TSH stimulation </strong>(by thyroid hormone withdrawal or recombinant TSH) to enhance iodine uptake.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Technetium-99m (Option B)</strong>&nbsp;is not used in the treatment of thyroid cancer but is commonly used in&nbsp;diagnostic imaging studies such as thyroid scans.</p>\n<p><strong>Phosphorus-32 (Option C)</strong>&nbsp;is not typically used in the treatment of thyroid cancer. It is used in&nbsp;systemic radionuclide&nbsp;therapy for conditions such as&nbsp;bone metastases, leukaemia, and polycythemia vera.</p>\n<p><strong>131 I - MIBG (Option D)&nbsp;</strong>is used in the treatment of certain&nbsp;neuroendocrine tumours&nbsp;such as&nbsp;pheochromocytoma and neuroblastoma, but it is not typically used in the treatment of thyroid cancer.</p>",
      "correct_choice_id": 191,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">X-rays</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">&beta; rays</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">&gamma; rays</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">&alpha; particles</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In radioiodine therapy for papillary carcinoma of the thyroid, the destruction of neoplastic thyroid cells is primarily mediated by:</span></p>",
      "unique_key": "DT1282691",
      "question_audio": null,
      "question_video": null,
      "map_id": 1282691,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The therapeutic efficacy of <strong>&sup1;&sup3;&sup1; I</strong> lies in its<strong> beta emission.</strong></p>\n<ul>\n<li><strong>Iodine-131 (&sup1;&sup3;&sup1; I)</strong> is the therapeutic isotope used for treating differentiated thyroid cancers like papillary carcinoma.</li>\n<li>It emits:\n<ul>\n<li><strong>&beta; particles (beta rays): </strong>These are high-energy electrons that cause localised cellular damage through DNA strand breaks and ionisation, leading to tumour cell death.</li>\n<li><strong>&gamma; rays: </strong>Used mainly for imaging, as they penetrate tissue and allow external detection but contribute little to therapeutic effect.</li>\n</ul>\n</li>\n<li><strong>&sup1;&sup3;&sup1; I </strong>has a tissue penetration of <strong>0.5 - 2 mm.</strong></li>\n<li>It is ideal for targeting <strong>residual thyroid tissue</strong> and <strong>micrometastases</strong> while sparing surrounding structures.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>X-rays (Option A)</strong> are artificially generated by LINAC and it is not produced by radioiodine for the treatment of papillary carcinoma thyroid.</p>\n<p><strong>Gamma (&gamma;) rays (Option C)</strong> are used for post-therapy imaging, not cell destruction.</p>\n<p><strong>&alpha; particles (Option D)</strong> are the products which least likely to be emitted by iodine-131.</p>",
      "correct_choice_id": 202,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}